Jan 13, 2017

Starpharma VivaGel® BV gets FDA fast track

Starpharma VivaGel® BV gets FDA fast track

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

 This contains certain forward-looking statements.